非那雄胺对前列腺癌发生率及病理分级的影响

目的:评估非那雄胺对中国人前列腺癌发病率及病理分级的影响.方法:将1 029例BPH患者根据其药物治疗的方法分为非那雄胺组、α-受体阻滞剂组、联合用药组及对照组(未治疗组).收集四组患者的穿刺病理资料,重新行Gleason评分.对四组患者前列腺癌发病率及前列腺癌病理分级的差异进行分析.结果:①前列腺癌总发病率为13.51%;应用非那雄胺组与未应用非那雄胺组比较差异有统计学意义(P<0.05),发病率相对下降40.63%(RR=0.59,95%CI:0.43～0.82).②前列腺癌患者病理分级为中高级(Gleason≥7分)者占58.27%,应用非那雄胺组与未应用非那雄胺组比较差异有统计学意义(P<0.05),中高级分化前列腺癌相对增多33.96%(RR=1.34,95%CI:1.01～1.76).结论:非那雄胺治疗BPH虽能降低前列腺癌的发病风险,但同时能使发生前列腺癌的病理级别增高.

The Influence of Finasteride on Incidence and Pathology Grading of Prostate Cancer

Objective:To evaluate the influence of finasteride on incidence and pathology grading of prostate ca-ner in China. Methods:Depend on the medication, 1029 patients with benign prostatic hyperplasia (BPH) were di-vided into 4 groups: finasteride group,α-receptor inhibitor group, eombination group and control group (non-treatment group). We gathered pathology sections of all patients, and gave Gleason Score to each. The difference the population was 13.51%. Compare with non-using of finasteride, using of it could reduee the incidence of pros-tate cancer 40.63% than non-using group's (RR = 0.59,95% CI: 0.43-0.82). There was a significant difference cancer patients was 58.27%, The ratio was quite different using finasteride and patients not (P<0.05), and it in-creased 33.96% in finasteride groups compare to not using groups(RR= 1.34,95%CI: 1.01-1.76). Conclusions: The risk of prostate eaneer in BPH patients could be decreased by finasteride treatment. But the malignant degree of prostate caner could be increased in BPH patients using finaseride.